A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (NCT05864144)
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: UCLA Hematology/Oncology — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- UCLA Hematology/Oncology — Los Angeles, California
- University of Colorado Cancer Center - Anschutz Medical — Aurora, Colorado
- Norton Healthcare — Louisville, Kentucky
- Henry Ford Cancer — Detroit, Michigan
- Icahn School of Medicine at Mt. Sinai — New York, New York
- University of Pennsylvania, Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Sanford Cancer Center — Sioux Falls, South Dakota
- NEXT Oncology Dallas — Irving, Texas
- South Texas Accelerated Research Therapeutics (START) San Antonio — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors — San Francisco, California
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.